David Plas

Affiliations: 
Cell & Molecular Biology University of Cincinnati, Cincinnati, OH 
Area:
Cell Biology
Google:
"David Plas"
BETA: Related publications

Publications

You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.

Bischoff ME, Shamsaei B, Yang J, et al. (2024) Copper drives remodeling of metabolic state and progression of clear cell renal cell carcinoma. Biorxiv : the Preprint Server For Biology
Shin S, Han MJ, Jedrychowski MP, et al. (2023) mTOR inhibition reprograms cellular proteostasis by regulating eIF3D-mediated selective mRNA translation and promotes cell phenotype switching. Cell Reports. 42: 112868
Verma R, Aggarwal P, Bischoff ME, et al. (2023) Macrotubule associated protein MAP1LC3C regulates lysosomal exocytosis and induces zinc reprogramming in renal cancer cells. The Journal of Biological Chemistry. 104663
Czyzyk-Krzeska MF, Meller J, Landero Figueroa JA, et al. (2021) Metabolic subtypes of clear cell renal cell carcinoma defined by tobacco smoking. Molecular & Cellular Oncology. 8: 1859917
Wang C, Haas MA, Yeo SK, et al. (2021) Autophagy mediated lipid catabolism facilitates glioma progression to overcome bioenergetic crisis. British Journal of Cancer
Wang C, Haas MA, Yang F, et al. (2019) Autophagic lipid metabolism sustains mTORC1 activity in TSC-deficient neural stem cells. Nature Metabolism. 1: 1127-1140
Ennis K, Sarma P, Wetzel C, et al. (2018) CBMT-16. A COMBINATION STRATEGY TO COUNTERACT PTEN-DEFICIENCY BY TARGETING THE S6 AND TAM KINASES IN GLIOBLASTOMA Neuro-Oncology. 20: vi35-vi35
Yoon SO, Shin S, Karreth FA, et al. (2017) Focal Adhesion- and IGF1R-Dependent Survival and Migratory Pathways Mediate Tumor Resistance to mTORC1/2 Inhibition. Molecular Cell
Li C, Liu X, Liu Y, et al. (2017) Tuberin Regulates Prostaglandin Receptor-mediated Viability, via Rheb, in mTORC1-hyperactive Cells. Molecular Cancer Research : McR
Liu H, Feng X, Ennis KN, et al. (2017) Pharmacologic Targeting of S6K1 in PTEN-Deficient Neoplasia. Cell Reports. 18: 2088-2095
See more...